Bronchitol® is a precision spray‐dried form of mannitol that is delivered to the lungs by a specially designed, portable inhaler. Bronchitol® improves lung function and helps to clear mucus from the lungs in patients suffering from cystic fibrosis. Patients are required to pass a tolerance test prior to being prescribed Bronchitol® to ensure that they are not hyperresponsive to mannitol.
Bronchitol® (inhaled mannitol) is commercialized in 14 countries. EffRx has an exclusive license agreement with Pharmaxis Ltd, a listed pharmaceutical research company in Australia, for the registration and commercialization of Bronchitol® in Switzerland.
EffRx obtained the Swiss Marketing Authorisation for the treatment of cystic fibrosis (CF) in adults and in children aged 6 years and above as an add‐on to best standards of care.
For more information about Bronchitol® see www.swissmedicinfo.ch